Last $1.71 USD
Change Today +0.03 / 1.79%
Volume 10.6K
NURO On Other Exchanges
Symbol
Exchange
NURO is not on other exchanges.
As of 8:10 PM 10/24/14 All times are local (Market data is delayed by at least 15 minutes).

neurometrix inc (NURO) Snapshot

Open
$1.66
Previous Close
$1.68
Day High
$1.71
Day Low
$1.66
52 Week High
12/10/13 - $4.25
52 Week Low
10/28/13 - $1.47
Market Cap
13.6M
Average Volume 10 Days
28.7K
EPS TTM
$-2.03
Shares Outstanding
7.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for NEUROMETRIX INC (NURO)

Related News

No related news articles were found.

neurometrix inc (NURO) Related Businessweek News

No Related Businessweek News Found

neurometrix inc (NURO) Details

NeuroMetrix, Inc., a medical device company, develops and markets products for the detection, diagnosis, and monitoring of peripheral nerve and spinal cord disorders, such as those associated with carpal tunnel syndrome, lumbosacral disc disease, spinal stenosis, and diabetes. The company focuses on the diagnosis and treatment of neurological complications of diabetes. Its marketed products include SENSUS pain therapy device, a transcutaneous electrical nerve stimulator used for chronic and intractable pain, such as painful diabetic neuropathy; NC-stat DPNCheck, a device used to evaluate systemic neuropathies, such as diabetic peripheral neuropathy (DPN); and ADVANCE NCS/EMG system, a platform for the performance of traditional nerve conduction studies and invasive electromyography procedures for the assessment of carpal tunnel syndrome, low back and leg pain, and DPN, as well as consumables and accessories. The company distributes its products through its direct sales force and independent sales representatives to physicians, clinics, hospitals, managed care organizations, retail health businesses, and independent distributors consisting of primary care, internal medicine, orthopedic and hand surgeons, pain medicine physicians, neurologists, physical medicine and rehabilitation, physicians, and neurosurgeons, as well as endocrinology and podiatry markets primarily in the United States, Europe, Asia, and the Middle East. NeuroMetrix, Inc. was founded in 1996 and is headquartered in Waltham, Massachusetts.

30 Employees
Last Reported Date: 02/24/14
Founded in 1996

neurometrix inc (NURO) Top Compensated Officers

Founder, Chairman, Chief Executive Officer, P...
Total Annual Compensation: $436.8K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $311.3K
Senior Vice President of Information Technolo...
Total Annual Compensation: $263.2K
Compensation as of Fiscal Year 2013.

neurometrix inc (NURO) Key Developments

NeuroMetrix Inc. Reports Results of DPNCheck (R) Study at the Diabetes Research Unit of the Ipswich Hospital NHS Trust

NeuroMetrix Inc. reported results from a DPNCheck(R) study conducted at the Diabetes Research Unit of the Ipswich Hospital NHS Trust in the United Kingdom. DPNCheck is a fast, accurate and quantitative point-of-care test for diabetic peripheral neuropathy, or DPN. The DPNCheck test addresses an unmet medical need for better and more cost-effective screening, diagnosing and monitoring of DPN. This complication affects over 50% of people with diabetes and leads to foot ulcers and limb amputation, as well as severe pain and an overall reduction in patient quality of life. The reported results were DPNCheck sural nerve amplitude and conduction velocity demonstrated high sensitivity and specificity of 0.7 -- 0.9 at all stages of neuropathy. DPNCheck sural nerve amplitude and conduction velocity were highly correlated to LDIFLARE measurements of small fiber neuropathy.

NeuroMetrix Names Frank McGillin as SVP and GM

NeuroMetrix reported that it has appointed Frank McGillin as Senior Vice President and General Manager. McGillin was most recently at Philips Oral Healthcare and Johnson & Johnson.

NeuroMetrix Appoints Frank McGillin as Senior Vice President and General Manager, Consumer

NeuroMetrix Inc. announced that it has appointed Frank McGillin as Senior Vice President and General Manager, Consumer. Mr. McGillin will be responsible for development of a consumer healthcare business built on the company's wearable therapeutic technology for treatment of chronic pain which was recently cleared by the FDA for over-the-counter use without a prescription requirement. Mr. McGillin brings to the company over 20 years experience building successful, high-growth consumer brands most recently at Philips Oral Healthcare and at Johnson & Johnson.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NURO:US $1.71 USD +0.03

NURO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Natus Medical Inc $33.07 USD -0.44
View Industry Companies
 

Industry Analysis

NURO

Industry Average

Valuation NURO Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1.9x
Price/Book 1.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales NM Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NEUROMETRIX INC, please visit www.neurometrix.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.